Literature DB >> 23828778

Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice.

Seongah Han1, Taro E Akiyama, Stephen F Previs, Kithsiri Herath, Thomas P Roddy, Kristian K Jensen, Hong-Ping Guan, Beth A Murphy, Lesley A McNamara, Xun Shen, Walter Strapps, Brian K Hubbard, Shirly Pinto, Cai Li, Jing Li.   

Abstract

Hepatic glucose overproduction is a major characteristic of type 2 diabetes. Because glucagon is a key regulator for glucose homeostasis, antagonizing the glucagon receptor (GCGR) is a possible therapeutic strategy for the treatment of diabetes mellitus. To study the effect of hepatic GCGR inhibition on the regulation of lipid metabolism, we generated siRNA-mediated GCGR knockdown (si-GCGR) in the db/db mouse. The hepatic knockdown of GCGR markedly reduced plasma glucose levels; however, total plasma cholesterol was increased. The detailed lipid analysis showed an increase in the LDL fraction, and no change in VLDL HDL fractions. Further studies showed that the increase in LDL was the result of over-expression of hepatic lipogenic genes and elevated de novo lipid synthesis. Inhibition of hepatic glucagon signaling via siRNA-mediated GCGR knockdown had an effect on both glucose and lipid metabolism in db/db mice.

Entities:  

Keywords:  diabetes mellitus; dyslipidemia; glucose

Mesh:

Substances:

Year:  2013        PMID: 23828778      PMCID: PMC3770075          DOI: 10.1194/jlr.M035592

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  27 in total

1.  Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

Authors:  Kyle W Sloop; Julia Xiao-Chun Cao; Angela M Siesky; Hong Yan Zhang; Diane M Bodenmiller; Amy L Cox; Steven J Jacobs; Julie S Moyers; Rebecca A Owens; Aaron D Showalter; Martin B Brenner; Achim Raap; Jesper Gromada; Brian R Berridge; David K B Monteith; Niels Porksen; Robert A McKay; Brett P Monia; Sanjay Bhanot; Lynnetta M Watts; M Dodson Michael
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

2.  In vivo measurement of plasma cholesterol and fatty acid synthesis with deuterated water: determination of the average number of deuterium atoms incorporated.

Authors:  F Diraison; C Pachiaudi; M Beylot
Journal:  Metabolism       Date:  1996-07       Impact factor: 8.694

3.  Hypolipemic action of glucagon in experimental endogenous lipemia in the rat.

Authors:  R P Eaton
Journal:  J Lipid Res       Date:  1973-05       Impact factor: 5.922

4.  Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans.

Authors:  K F Petersen; J T Sullivan
Journal:  Diabetologia       Date:  2001-11       Impact factor: 10.122

5.  Effects of glucagon on plasma lipids in different types of primary hyperlipoproteinemia.

Authors:  F Aubry; Y L Marcel; J Davignon
Journal:  Metabolism       Date:  1974-03       Impact factor: 8.694

6.  Glycemic control in mice with targeted disruption of the glucagon receptor gene.

Authors:  Janice C Parker; Kim M Andrews; Melanie R Allen; Jeffrey L Stock; John D McNeish
Journal:  Biochem Biophys Res Commun       Date:  2002-01-18       Impact factor: 3.575

7.  A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects.

Authors:  Sajjad A Qureshi; Mari Rios Candelore; Dan Xie; Xiaodong Yang; Laurie M Tota; Victor D-H Ding; Zhihua Li; Alka Bansal; Corin Miller; Sheila M Cohen; Guoqiang Jiang; Ed Brady; Richard Saperstein; Joseph L Duffy; James R Tata; Kevin T Chapman; David E Moller; Bei B Zhang
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

8.  In vivo measurement of fatty acids and cholesterol synthesis using D2O and mass isotopomer analysis.

Authors:  W N Lee; S Bassilian; H O Ajie; D A Schoeller; J Edmond; E A Bergner; L O Byerley
Journal:  Am J Physiol       Date:  1994-05

9.  Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice.

Authors:  Yin Liang; Melville C Osborne; Brett P Monia; Sanjay Bhanot; William A Gaarde; Chantal Reed; Pengxiang She; Thomas L Jetton; Keith T Demarest
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

Review 10.  Lipids and lipoproteins in patients with type 2 diabetes.

Authors:  Ronald M Krauss
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

View more
  13 in total

1.  Kidney triglyceride accumulation in the fasted mouse is dependent upon serum free fatty acids.

Authors:  Diego Scerbo; Ni-Huiping Son; Alaa Sirwi; Lixia Zeng; Kelli M Sas; Vincenza Cifarelli; Gabriele Schoiswohl; Lesley-Ann Huggins; Namrata Gumaste; Yunying Hu; Subramaniam Pennathur; Nada A Abumrad; Erin E Kershaw; M Mahmood Hussain; Katalin Susztak; Ira J Goldberg
Journal:  J Lipid Res       Date:  2017-04-12       Impact factor: 5.922

2.  Glucagon's effect on liver protein metabolism in vivo.

Authors:  Guillaume Kraft; Katie C Coate; Jason J Winnick; Dominique Dardevet; E Patrick Donahue; Alan D Cherrington; Phillip E Williams; Mary Courtney Moore
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-05-23       Impact factor: 4.310

3.  Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity.

Authors:  Lale Ozcan; Xiaoming Xu; Shi-Xian Deng; Devram S Ghorpade; Tiffany Thomas; Serge Cremers; Brian Hubbard; Michael H Serrano-Wu; Matthias Gaestel; Donald W Landry; Ira Tabas
Journal:  Diabetes       Date:  2015-06-11       Impact factor: 9.461

4.  Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol.

Authors:  Stefano Spolitu; Haruka Okamoto; Wen Dai; John A Zadroga; Erika S Wittchen; Jesper Gromada; Lale Ozcan
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

5.  The hepatitis C virus core protein inhibits adipose triglyceride lipase (ATGL)-mediated lipid mobilization and enhances the ATGL interaction with comparative gene identification 58 (CGI-58) and lipid droplets.

Authors:  Gregory Camus; Martina Schweiger; Eva Herker; Charles Harris; Andrew S Kondratowicz; Chia-Lin Tsou; Robert V Farese; Kithsiri Herath; Stephen F Previs; Thomas P Roddy; Shirly Pinto; Rudolf Zechner; Melanie Ott
Journal:  J Biol Chem       Date:  2014-11-07       Impact factor: 5.157

Review 6.  Multi-organ Coordination of Lipoprotein Secretion by Hormones, Nutrients and Neural Networks.

Authors:  Priska Stahel; Changting Xiao; Avital Nahmias; Lili Tian; Gary Franklin Lewis
Journal:  Endocr Rev       Date:  2021-11-16       Impact factor: 19.871

7.  Glucagon receptor antagonism induces increased cholesterol absorption.

Authors:  Hong-Ping Guan; Xiaodong Yang; Ku Lu; Sheng-Ping Wang; Jose M Castro-Perez; Stephen Previs; Michael Wright; Vinit Shah; Kithsiri Herath; Dan Xie; Daphne Szeto; Gail Forrest; Jing Chen Xiao; Oksana Palyha; Li-Ping Sun; Paula J Andryuk; Samuel S Engel; Yusheng Xiong; Songnian Lin; David E Kelley; Mark D Erion; Harry R Davis; Liangsu Wang
Journal:  J Lipid Res       Date:  2015-09-15       Impact factor: 6.676

8.  Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes.

Authors:  Ursula H Neumann; Jessica S S Ho; Sam Chen; Yuen Yi C Tam; Pieter R Cullis; Timothy J Kieffer
Journal:  Mol Metab       Date:  2017-06-22       Impact factor: 7.422

9.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

10.  The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys.

Authors:  Sheo B Singh; Ling Kang; Andrea R Nawrocki; Dan Zhou; Margaret Wu; Stephen Previs; Corey Miller; Haiying Liu; Catherine D G Hines; Maria Madeira; Jin Cao; Kithsiri Herath; Larry D Spears; Liangsu Wang; David E Kelley; Cai Li; Hong-Ping Guan
Journal:  PLoS One       Date:  2016-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.